Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Max M Lenders"'
Autor:
Carola Berking, Thomas K Eigentler, Andrea Forschner, Georg Richtig, Erika Richtig, Stefan Diem, Benjamin Weide, Bernhard Klumpp, Claus Garbe, Lukas Flatz, Patrick Terheyden, Lydia Reinhardt, Friedegund Meier, Carmen Loquai, Ulrike Leiter, Van Anh Nguyen, Martin Röcken, Mirjana Ziemer, Nikolaus B Wagner, Max M Lenders, Kathrin Kühl, Fiona André, Milena Dudda, Natalie Ring, Chiara Ebel, Ramon Stäger, Caroline Zellweger, Roland Lang, Michael Paar, Philipp Gussek, Suzan H Stürmer, Susanne Kimeswenger, Angela Oellinger, Maximilian Gassenmaier, Amadeus Schraag, Wolfram Hoetzenecker, Johanna Mangana, Christoffer Gebhardt, Antonio Cozzio
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Background Checkpoint inhibitors revolutionized the treatment of metastatic melanoma patients. Although tumor burden and lactate dehydrogenase (LDH) are associated with overall survival (OS), the impact of tumor growth kinetics remains elusive and in
Externí odkaz:
https://doaj.org/article/312f3dbada1340769c33f2cc069c254d
Autor:
Ulrike Leiter, Max M Lenders, Thomas Eigentler, Benjamin Weide, Claus Garbe, Maximilian Gassenmaier, Andrea Forschner, Nikolaus B. Wagner
Publikováno v:
Targeted Oncology
Background Despite impressive response rates, most patients with advanced melanoma ultimately progress following therapy with B-Raf proto-oncogene (BRAF) inhibitors (BRAFi). Therefore, frequent radiologic assessments are necessary, and reliable serum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3345215c584350580d3089a7cc008126
http://europepmc.org/articles/PMC7935737
http://europepmc.org/articles/PMC7935737
Autor:
Andrea Forschner, Maximilian Gassenmaier, Max M Lenders, Johanna Winter, Ulrike Leiter, Nikolaus B. Wagner, Thomas Eigentler, Claus Garbe, Antonio Cozzio, Mette-Triin Purde, Lukas Flatz, Martin Röcken, Benjamin Weide
Publikováno v:
Cancer Immunology, Immunotherapy. 70:1089-1099
Hepatic immune-related adverse events (irAE) including elevated liver function tests (transaminases) occur in 1.4–22.3% of melanoma patients receiving immune checkpoint inhibitors (ICPI) and constitute a potentially serious toxicity that is challen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a07696d394db04260ffa92be23d3baa1
https://doi.org/10.1007/s00262-020-02768-5
https://doi.org/10.1007/s00262-020-02768-5
Autor:
Ramon Stäger, Suzan Stürmer, Carola Berking, Philipp Gussek, Fiona André, Amadeus Schraag, Chiara Ebel, Max M Lenders, Lydia Reinhardt, Lukas Flatz, Stefan Diem, Roland Lang, Martin Röcken, Susanne Kimeswenger, Mirjana Ziemer, Georg Richtig, Milena Dudda, Ulrike Leiter, J. Mangana, Bernhard Klumpp, Thomas Eigentler, Christoffer Gebhardt, Michael Paar, Claus Garbe, Van Anh Nguyen, Benjamin Weide, Patrick Terheyden, Maximilian Gassenmaier, Antonio Cozzio, Andrea Forschner, Friedegund Meier, Wolfram Hoetzenecker, Carmen Loquai, Angela Oellinger, Kathrin Kühl, Caroline Zellweger, Nikolaus B. Wagner, Erika Richtig, Natalie Ring
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundCheckpoint inhibitors revolutionized the treatment of metastatic melanoma patients. Although tumor burden and lactate dehydrogenase (LDH) are associated with overall survival (OS), the impact of tumor growth kinetics remains elusive and in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::227bc99f1fff4a412e4f80794a8bf81c
https://mediatum.ub.tum.de/doc/1653380/document.pdf
https://mediatum.ub.tum.de/doc/1653380/document.pdf
Autor:
Johanna, Winter, Max M, Lenders, Maximilian, Gassenmaier, Andrea, Forschner, Ulrike, Leiter, Benjamin, Weide, Mette-Triin, Purde, Lukas, Flatz, Antonio, Cozzio, Martin, Röcken, Claus, Garbe, Thomas K, Eigentler, Nikolaus B, Wagner
Publikováno v:
Cancer immunology, immunotherapy : CII. 70(4)
Hepatic immune-related adverse events (irAE) including elevated liver function tests (transaminases) occur in 1.4-22.3% of melanoma patients receiving immune checkpoint inhibitors (ICPI) and constitute a potentially serious toxicity that is challengi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5e39d2004c4f5452ed647ea49fb08fe4
https://pubmed.ncbi.nlm.nih.gov/33113003
https://pubmed.ncbi.nlm.nih.gov/33113003